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: Process for the preparation of Gadolinium-based contrast agents a

Process for the preparation of Gadolinium-based contrast agents and its
intermediates
The present publication relates to a process for the preparation of 1,4,7Tris(carboxymethyl)-10-(1-(hydroxymethyl)-2,3-dihydroxypropyl)-1,4,7,105

tetraazacyclododecane represented by the following structural formula-1, which is
referred to as Butrol.

Formula-1.
Butrol is an intermediate used for the preparation of 10-[(1SR,2RS)-2,310

dihydroxy-1-hydroxymethylpropyl]-1,4,7,10-tetraazacyclododecane-1,4,7–triacetic
acid, gadolinium complex is known as Gadobutrol of formula-1a and calcium
complex

of

10-(2,3-Dihydroxy-l-(hydroxymethyl)propyl)-1,4,7,10-tetraaza-

cyclodecane-1,4,7-triacetic acid is known as Calcobutrol of formula-1b.

Background of the invention:
15

10-[(1SR,2RS)-2,3-dihydroxy-1-hydroxymethylpropyl]-1,4,7,10tetraazacyclododecane-1,4,7–triacetic

acid,

gadolinium

complex

or

10-(2,3-

dihydroxy-1-hydroxymethylpropyl)-1,4,7,10-tetraazacyclododecane-1,4,7-triacetic
acid, Gd Complex of formula-1a is commonly known as Gadobutrol, it is a
gadolinium-based contrast agent indicated for intravenous use in diagnostic MRI in
20

adults and children (2 years of age and older) to detect and visualize areas with
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disrupted blood brain barrier (BBB) and/or abnormal vascularity of the central
nervous system s with the brand name of Gadavist®.
Food and Drug Administration label published on 14 March 2011 on Food and
Drug administration website discloses chemical structure of Gadobutrol as follows:

5
The journal article Inorganic Chemistry 1997, 36 (26), 6086–6093 and the
patent document US10072027B2 discloses chemical structure of Gadobutrol as
follows:

10

Gadobutrol is a racemic metal coordination complex of gadolinium (Gd3+).
The carbons at 1-Hydroxymethyl and 2 hydroxy position of Gadobutrol are achiral.
Therefore, both structure represetations of Gadobutrol in Food and Drug
administration label and Inorganic Chemistry, 1997, 36 (26), 6086–6093 journal
article can be used interchangeably. For convenience, applicants of the present

15

application followed the chemical structure representation of Gadobutrol and its
intermediates similar to Inorganic Chemistry 1997, 36 (26), 6086–6093.
Calcobutrol is an additive in the galenic formulations of Gadobutrol and
solves the problem of preventing the release of free gadolinium in the formulations
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(solutions).
Gadobutrol and its process for the preparation is described in US5980864.
Gadobutrol preparation is also disclosed in the WO2012143355, Inorganic Chemistry
1997, 36, 6086- 6093, US6894151, WO2020012372 and WO2020040617.
5

Brief Description of the Drawings:
Figure-1: Illustrates the PXRD pattern of amorphous Calcobutrol sodium.
Detailed description of the Invention:
The “suitable solvent” used in the present invention can be selected from but

10

not limited to “hydrocarbon solvents” such as n-pentane, n-hexane, n-heptane,
cyclohexane, petroleum ether, benzene, toluene, xylene and mixtures thereof; “ether
solvents” such as dimethyl ether, diethyl ether, diisopropyl ether, methyl tert-butyl
ether, 1,2-dimethoxyethane, tetrahydrofuran, 1,4-dioxane and mixtures thereof; “ester
solvents” such as methyl acetate, ethyl acetate, n-propyl acetate, isopropyl acetate, n-

15

butyl acetate, isobutyl acetate, tert-butyl acetate and mixtures thereof; “polar-aprotic
solvents” such as dimethylacetamide, dimethylformamide, dimethylsulfoxide, Nmethylpyrrolidone (NMP) and mixtures thereof; “chloro solvents” such as
dichloromethane, dichloroethane, chloroform, carbon tetrachloride and mixtures
thereof; “ketone solvents” such as acetone, methyl ethyl ketone, methyl isobutyl

20

ketone and mixtures thereof; “nitrile solvents” such as acetonitrile, propionitrile,
isobutyronitrile and mixtures thereof; “alcohol solvents” such as methanol, ethanol,
n-propanol, iso-propanol, n-butanol, iso-butanol, 2-butanol, tert-butanol, ethane-1,2diol, propane-1,2-diol and mixtures thereof; “polar solvents” such as water; formic
acid, acetic acid and the like or mixture of any of the afore mentioned solvents.

25
The term “base” used in the present invention refers to inorganic bases
selected from “alkali metal carbonates” such as sodium carbonate, potassium
carbonate, lithium carbonate, cesium carbonate and the like; “alkali metal
bicarbonates” such as sodium bicarbonate, potassium bicarbonate, lithium
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bicarbonate, cesium bicarbonate and the like; “alkali metal hydroxides” such as
sodium hydroxide, potassium hydroxide, lithium hydroxide and the like; “alkyl
metals” such as n-butyl lithium and like; “metal hydrides” such as lithium hydride,
sodium hydride, potassium hydride and the like; “alkali metal phosphates” such as
5

disodium hydrogen phosphate, dipotassium hydrogen phosphate; ammonia such as
aqueous ammonia, ammonia gas, methanolic ammonia and like and “organic bases”
selected from but not limited to methyl amine, ethyl amine, diisopropyl amine,
diisopropylethyl amine (DIPEA), diisobutylamine, triethylamine, tert.butyl amine,
pyridine, 4-dimethylaminopyridine (DMAP), N-methyl morpholine (NMM), nmethyl

10

pyridine (NMP), 1,8-diazabicyclo[5.4.0]undec-7-ene (DBU), 1,5-diazabicyclo[4.3.0]
non-5-ene (DBN), 1,4-diazabicyclo[2.2.2]octane (DABCO), imidazole; “alkalimetal
alkoxides” such as sodium methoxide, sodium ethoxide, potassium methoxide,
potassium ethoxide, sodium tert.butoxide, potassium tert.butoxide and the like;
“alkali metal amides” such as sodium amide, potassium amide, lithium amide,

15

lithiumdiisopropyl amide (LDA), sodium bis(trimethylsilyl)amide (NaHMDS),
potassiumbis(trimethylsilyl)amide, lithium bis(trimethysilyl)amide (LiHMDS) and
the like; or mixtures thereof.
As used herein the term “acid” in the present invention refers to inorganic acid
and organic acid; inorganic acid is selected from such as hydrochloric acid,

20

hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid, sulfuric acid; organic
acids such as acetic acid, maleic acid, malic acid, oxalic acid, succinic acid, fumaric
acid, trifluoroacetic acid, methane sulfonic acid, p-toluene sulfonic acid; chiral acids
such as S-(+) mandelic acid, R-(-) mandelic acid, L-(+)tartaric acid, D-(-)tartaric
acid, L-malic acid, D-malic acid, D-maleic acid, (-)-naproxen, (+)-naproxen, (1R)-

25

(-)-camphor sulfonic acid, (IS)-(+)-camphor sulfonic acid (1R)-(+)-bromocamphor10-sulfonic acid, (1S)-(-)-bromocamphor-10-sulfonic acid, (-)-Dibenzoyl-L-tartaric
acid, (-)-Dibenzoyl-L-tartaricacid monohydrate, (+) -Dibenzoyl-D-tartaric acid, (+)Dibenzoyl-D-tartaric

acid

monohydrate,

(+)-dipara-tolyl-D-tataric

acid,

(-)-

diparatolyl-L-tataricacid, L(-)-pyroglutamic acid, L(+)-pyroglutamic acid, (-)-lactic
4
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acid.
First embodiment of the present invention provides a process for the
preparation
5

of

1,4,7-tris(carboxymethyl)-10-(1-(hydroxymethyl)-2,3-dihydroxy

propyl)-1,4,7,10-tetraazacyclododecane formula-1 comprising hydrolysis of 1,4,7tris(tert-butoxycarbonylmethyl)-10-(6-hydroxy-2,2-dimethyl-1,3-dioxepane-5-yl)1,4,7,10-tetraazacyclododecane compound of formula-2 using water, optionally in
presence of catalytic amount of an acid in a solvent to provide 1,4,7tris(carboxymethyl)-10-(1-(hydroxymethyl)-2,3-dihydroxypropyl)-1,4,7,10-tetraaza

10

cyclododecane compound of formula-1.
Acid in step-a) is same as defined above; wherein the acid is used in less than
about 0.5 equivalents with respect to formula-2; solvent in step-a) is selected from
alcohol solvents, ether solvents, ketone solvents, ester solvents, amide solvents, water
and/or mixtures thereof.

15

In the first aspect of first embodiment, the compound of formula-1 can be
converted into Gadobutrol of formula-1a by treating the compound of formula-1 with
gadolinium oxide in a solvent to provide Gadobutrol of formula-1a.

20

Scheme-1
In the second aspect of first embodiment, the compound of formula-1 can be
converted into Calcobutrol of formula-1b by treating the compound of formula-1 with
calcium carbonate or calcium oxide or calcium hydroxide in a solvent to provide the
Calcobutrol of formula-1b.

5
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Scheme-2

In third aspect of the first embodiment, intermediate butrol of formula 1 of the
5

present invention can be converted into Gadobutrol or Calcobutrol by processes
known in the art, such as Inorganic Chemistry 1997, 36, 6086- 6093 or as the process
described in the present application.
In fourth aspect of first embodiment hydrolysis facilitates the removal of tbutoxy and removal of 2,2-dimethyl protecting group.

10
Calcobutrol of formula-1b optionally converted to its sodium salt by treating
with sodium source. The sodium source is selected from sodium bases such as
sodium carbonate, sodium bicarbonate, sodium hydroxide, sodium methoxide,
sodium hydrogen citrate, sodium citrate, sodium acetate, sodium propionate, sodium
15

butyrate, sodium isobutyrate, sodium tartrate, sodium oxalate, sodium benzoate,
sodium sorbate, sodium malate, monosodium succinate, disodium succinate.

The compound of formula-1a produced by the processes of the present
invention can be further micronized or milled to get desired particle sizes to achieve
20

desired solubility profile based on different forms of pharmaceutical composition
requirements. Techniques that may be used for particle size reduction include but not
limited to a single or multi-stage micronization using cutting mills, pin/cage mills,
hammer mills, jet mills, fluidized bed jet mills, ball mills and roller mills. Milling or
micronization may be performed before drying or after drying of the product.

6
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Second embodiment of the present invention provides the use of Gadobutrol
of formula-1a and/or Calcobutrol of formula-1b of the present invention for the
preparation of various pharmaceutical formulations.
5
Third embodiment of the present invention provides pharmaceutical
composition comprising Gadobutrol of formula-1a and/or and Calcobutrol of
formula-1b and their polymorphs or mixture thereof obtained according to the present
invention and at least one pharmaceutically acceptable excipient.
10
Fourth embodiment of the present invention provides the process for the
preparation of Calcobutrol sodium comprising treating Calcobutrol with sodium
bicarbonate in solvent.
In first aspect of fourth embodiment wherein solvent is selected from alcohol
15

solvents, ether solvents, ketone solvents, ester solvents, amide solvents, water and/or
mixtures thereof.
In second aspect of fourth embodiment of the present invention provides a
substantially pure compound of Calcobutrol sodium having HPLC (High
performance liquid chromatography) purity greater than about 99% or greater than

20

about 99.5% or greater than about 99.6% or greater than about 99.8% or greater than
about 99.9% as measured by HPLC (High performance liquid chromatography)
method.
In third aspect of fourth embodiment Calcobutrol sodium is in amorphous
form.

25

"Substantially pure" or “pure” in relation to Calcobutrol sodium or amorphous
form of Calcobutrol sodium prepared by the process of the present invention is
substantially free from the impurities. The said compound of Calcobutrol sodium or
amorphous form of Calcobutrol sodium obtained according to the present invention is
substantially pure having a purity of greater than about 99%, preferably greater than

30

about 99.5% by HPLC.
7
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As used herein, the term "pharmaceutical compositions" or "pharmaceutical
formulations" include tablets, pills, powders, liquids, suspensions, emulsions,
granules, capsules, suppositories, or injection preparations.
The term “pharmaceutically acceptable excipients” selected from but not

5

limited to binders, diluents, disintegrants, surfactants and lubricants. Suitable binders
that can be include polyvinylpyrolidone, copovidone, starches such as pregelatinized
starch, cellulose derivatives such as hydroxypropylmethyl cellulose, ethylcellulose,
hydroxypropylcellulose and carboxymethylcellulose, gelatine, acacia, agar, alginic
10

acid, carbomer, chitosan, dextrates, cyclodextrin, dextrin, glycerol dibehenate,
guargum, hypromellose, maltodextrin, poloxamer, polycarbophil, polydextrose,
polyethylene oxide, polymethacrylates, sodium alginate, sucrose, mixtures thereof;
suitable diluents that can be include anhydrous lactose, lactose monohydrate,
modified

15

lactose,

dibasic

calcium

phosphate,

tribasic

calcium

phosphate,

microcrystalline cellulose, silicified microcrystalline cellulose, powdered cellulose,
maize starch, pregelatinized starch, calcium carbonate, sucrose, glucose, dextrates,
dextrins, dextrose, fructose, lactitol, mannitol, sorbitol starch, calcium lactate or
mixtures thereof; suitable disintegrants that can be include magnesium aluminometa
silicate (or magnesium aluminum silicate), starch, pregelatinized starch, sodium

20

starch

glycolate,

crospovidone,

croscarmellose

sodium,

low-substituted

hydroxypropyl cellulose, alginic acid, carboxy methyl cellulose sodium, sodium
alginate, calcium alginate and chitosan; suitable lubricants that can be include (but are
not limited to) magnesium stearate, stearic acid, palmitic acid, talc, and aerosil.
Suitable surfactants that can be include (but are not limited to) polysorbate 80,
25

polyoxyethylene sorbitan, polyoxyethylene-polyoxy-propylene copolymer

and

sodium lauryl sulphate; beta-cyclodextrin include (but are not limited to)
sulfobutylalkyl

ether-beta-cyclodextrin,

betadex-sulfobutylether

sodium,

or

hydroxypropyl-beta-cyclodextrin.

8
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Gadobutrol of formula-1a and their polymorphs produced by the present
invention is indicated for intravenous use in diagnostic MRI in adults and children (2
years of age and older) to detect and visualize areas with disrupted blood brain barrier
(BBB) and/or abnormal vascularity of the central nervous system.
5
The best mode of carrying out the present invention was illustrated by the
below mentioned examples. These examples are provided as illustration only and
hence should not be construed as limitation to the scope of the invention.
Examples:
10

Example-1: Preparation of 1-Formyl-7-(6-hydroxy-2,2-dimethyl-1,3-dioxepane5-yl)-1,4,7,-10-tetraazacyclododecane
Mixture of 1,4,7,10-Tetraazacyclododecane (100 g), toluene (500 ml) and 1,1dimethoxy-N,N-dimethyl methanamine (76 g) is heated to 95-100°C and stirred at
the same temperature. Cooled the reaction to 70°C and distilled off solvent

15

completely. 4,4-Dimethyl-3,5,8-trioxabicyclo[5,1,0]octane (83.68 g) was added to the
obtained compound at 25-30°C, heated to 115-120°C and stirred at the same
temperature. Cooled the reaction mixture to 90-95°C, water is added to it and further
cooled to 25-30°C. Methanol (400 ml) was added to mixture at 25-30°C, stirred at
the same temperature and distilled off solvent completely. Co-distilled with

20

acetonitrile. Recrystallized the obtained compound using acetonitrile to get the pure
title compound.
Yield: 107.0 g; Purity by HPLC: 99.20%.
Example-2:

Preparation

of

1,4,7-Tris(tert-butoxycarbonylmethyl)-10-(6-

hydroxy-2,2-dimethyl-1,3-dioxepane-5-yl)-1,4,7,10-tetraazacyclododecane
25

of

formula-2
Mixture of 1-Formyl-7-(6-hydroxy-2,2-dimethyl-1,3-dioxepane-5-yl)-1,4,7,-10-tetraazacyclododecane (100 g), sodium hydroxide (58 g), water (100 ml) and methanol
(200 ml) was heated to 60-65°C and stirred at the same temperature. Distilled off the
solvent completely from the reaction mixture. Water and toluene were added to
9
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obtained compound at 25-30°C, heated the mixture to 50-55°C and stirred at the
same temperature. Separated the organic and aqueous layers and aqueous layer was
extracted with toluene. Combined the organic layers. Sodium carbonate (107 g) and
tert-butyl bromoacetate (198.1 g) slowly added to toluene layer at 25-30°C and
5

stirred at the same temperature. Water was added to the reaction mixture at 25-30°C
and stirred at the same temperature. Filtered the obtained solid and washed with
water. Water was added to wet solid and acidified using acetic acid. Methyl tertiary
butyl ether was added to mixture at 25-30°C and basified using aqueous ammonia
solution. Separated the both organic layer and the aqueous layer was extracted with

10

methyl tertiary butyl ether. Combined the organic layers and distilled off the solvent
completely. Water was added to obtained compound at 25-30°C and stirred at the
same temperature. Filter the solid, washed with water dried to get the tile compound.
Yield: 120 g; Purity of HPLC: 99.34%
Example-3: Preparation of Butrol of formula-1

15

1,4,7-Tris(tert-butoxycarbonylmethyl)-10-(6-hydroxy-2,2-dimethyl-1,3-dioxepane-5yl)-1,4,7,10-tetraazacyclododecane (60 g) and water (300 ml) at 25-30°C was heated
to 95-100°C and stirred at the same temperature. Cooled the reaction mixture to 2530°C. The reaction mixture washed with dichloromethane. Distilled off the solvent
and co-distilled with isopropanol. To the obtained compound isopropanol (300 ml)

20

was added at 60-65°C and stirred at the same temperature. Cooled the mixture to 2530°C. Filtered the solid, washed with isopropanol and dried to get the title compound.
Yield: 30 g.
Example-4: Preparation of Gadobutrol of formula-1a
Mixture of 1,4,7-Tris(tert-butoxycarbonylmethyl)-10-(6-hydroxy-2,2-dimethyl-1,3-

25

dioxepane-5-yl)-1,4,7,10-tetraazacyclododecane (200 g), trifluoroacetic acid (8.65 g)
and water (200 ml) at 25-30°C was heated to 95-100°C and stirred the reaction
mixture at the same temperature. Cooled the reaction mixture to 25-30°C,
dichloromethane added and separated both organic and aqueous layers. Aqueous
layer washed with dichloromethane. Gadalonium oxide (66 g) was added to obtained
10
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aqueous layer, heated to 95-100°C and stirred at the same temperature. Cooled the
reaction mixture to 25-30°C, filtered the reaction mixture and washed with water. To
the filtrate Indion 225 H resin was added and stirred at 25-30°C. The mixture was
filtered and washed with water. Basic resin was added to the filtrate and stirred the
5

mixture. The mixture was filtered and washed with water. The obtained filtrate was
treated with carbon. Distilled off the solvent from the filtrate completely under
vacuum. To the obtained compound water (200 ml) and ethanol (400 ml) was added
and heated to 80-85°C. Ethanol (3000 ml) was slowly added to the mixture 80-85°C
and stirred at the same temperature. Cool the mixture to 25-30°C and stirred at the

10

same temperature. Filtered the solid and washed with ethanol. Water (100 ml) and
methanol (600 ml) were added to the obtained compound at 25-30°C and heated the
60-65°C temperature. Methanol (2400 ml) added at 61-62°C and stirred at the same
temperature. Cooled the mixture to 25-30°C, filter the solid, washed with ethanol and
dried to get the title compound.

15

Yield: 120 g; Purity by HPLC: 99.92%
Example-5: Purification of Gadobutrol
Ethanol (250 ml) was added to the mixture of water (250 ml) and Gadobutrol (250 g)
at 25-30°C and stirred at the same temperature. Filtered the mixture and filtrate was
heated to 80-85°C and stirred at the same temperature. Ethanol (3250 ml) was slowly

20

added to mixture at 80-85°C and stirred at the same temperature. Cooled the mixture
to 25-30°C and stirred at the same temperature. Filtered the solid, washed with
ethanol and dried to get the title compound.
Yield: 200 g; Purity by HPLC: 99.95%
Example-8: Preparation of Calcobutrol

25

Mixture of 1,4,7-Tris(tert-butoxycarbonylmethyl)-10-(6-hydroxy-2,2-dimethyl-1,3dioxepane-5-yl)-1,4,7,10-tetraazacyclododecane (150 g), trifluoroacetic acid (2.59 g)
and water (600 ml) at 25-30°C was heated to 95-100°C and stirred the reaction
mixture at the same temperature. Cooled the reaction mixture to 25-30°C,
dichloromethane added and separated both organic and aqueous layers. Aqueous
11
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layer washed with dichloromethane. Calcium carbonate (22.7 g) was added to
obtained aqueous layer at 28-30°C and stirred at the same temperature. Filtered the
reaction mixture and washed with water. Distilled off the solvent completely from the
filtrate under vacuum and further co-distilled with ethanol. Ethanol (3000 ml) was
5

added to obtained compound at 55-60°C and stirred at the same temperature. Cool
the mixture to 5-10°C and stirred at the same temperature. Filtered the solid and
washed with ethanol. Methanol (750 ml) added to obtained compound at 25-30°C,
heated the reaction mixture to 60-65°C and stirred at the same temperature. Cooled
the mixture to 25-30°C and stirred at the same temperature. Filter the solid, washed

10

with methanol and dried to get the title compound.
Yield: 83 g; Purity by HPLC: 99.56%.
Example-6: Preparation of Calcobutrol sodium
Mixture of Calcobutrol (150 g), water (750 ml) and sodium bicarbonate (25.8 g)
stirred at 25-30°C. Filter the reaction mixture, washed with water and distilled off

15

solvent completely. Acetone (750 ml) added to obtained compound at 25-30°C,
heated to 40-45°C and stirred at the same temperature. Cooled the mixture to 2530°C and stirred at the same temperature. Filter the solid, washed with acetone and
dried to get the title compound.
Yield: 120 g; Purity by HPLC: 99.80%; PXRD pattern of the obtained compound is

20

depicted in figure-1.

25
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https://www.tdcommons.org/dpubs_series/5244

13

: Process for the preparation of Gadolinium-based contrast agents a

5

Figure-1

*****************
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